Genticel Secures $23.7 Million in Capital Funding
4/24/2013 7:24:07 AM
More...
|
Genticel Announces Positive Data From Its Phase I Trial in Women Infected With High-Risk HPV Before Appearance of Cervical Lesions
10/18/2012 1:05:44 PM
More...
|
Genticel Completed Recruitment for Its Phase Ib Vaccine Trial in Women Infected With High-risk HPV
2/21/2012 9:28:38 AM
More...
|
Genticel Has Completed Recruitment of Patients for its Phase I Trial With Procervix, its Therapeutic Vaccine Against Human Papillomavirus (HPV) Types 16 and 18
10/19/2011 11:36:14 AM
More...
|
Genticel Names Dr Didier Hoch, Former President of Sanofi Pasteur (SASY.PA) MSD, to its Supervisory Board
7/6/2011 1:05:14 PM
More...
|
Genticel’s Therapeutic Vaccine, Procervix, Aimed At Preventing Cervical Cancer In Patients Already Infected By Human Papillomavirus (HPV), Receives Clearance To Start A Phase I Clinical Trial
7/23/2010 11:21:28 AM
More...
|
BT PHARMA Secures USD 17.7 Million in Capital Funding and Changes its Name to Genticel
3/9/2010 10:07:28 AM
More...
|